Bayer, Whitehall NDAs for ketoprofen switch; OTC Zantac on July 13-14 NDAC agenda.
This article was originally published in The Tan Sheet
BAYER, WHITEHALL-ROBINS' KETOPROFEN Rx-TO-OTC SWITCHES SET FOR NDAC REVIEW at a July 14 joint meeting with FDA's Arthritis Advisory Committee. Bayer Consumer Care and American Home Products subsidiary Whitehall-Robins filed separate NDAs in support of ketoprofen 12.5 mg for the over-the-counter treatment of pain and fever. The joint meeting of the Nonprescription Drugs and Arthritis Advisory Committees begins 8:30 a.m. in conference rooms D&E of FDA's Parklawn Building in Rockville, Md.
You may also be interested in...
Perrigo promotes in pricing, planning
Combe sells most of its OTC brands
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC